Li Kang Biomedical Co., Ltd. (TPEX:6242)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
34.00
0.00 (0.00%)
Sep 11, 2026, 12:52 PM CST

Li Kang Biomedical Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
76.3983.8277.02110.99112.0951.44
Depreciation & Amortization
7.118.7912.4311.7410.9912.89
Loss (Gain) From Sale of Investments
-0.520.46-0.28-0.92.21.75
Stock-Based Compensation
--4.64---
Other Operating Activities
-8.42-4.1-29.45-5.413.2-8.71
Change in Accounts Receivable
2.650.18-0.250.92-2.15-0.59
Change in Inventory
-14.77-0.7-3.66-8.79-4.252.64
Change in Accounts Payable
10.44-1.074.57-83.768.18
Change in Other Net Operating Assets
3.434.760.35-3.8221.41-7.16
Operating Cash Flow
76.3192.1565.3896.74157.2460.45
Operating Cash Flow Growth
-10.63%40.94%-32.42%-38.48%160.14%-25.98%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-253.74-329.38-62.75-3.26-1.16-4.25
Sale (Purchase) of Intangibles
-0.28-0.17-1.98--1.54-0.2
Investment in Securities
128.59241.24-199.54-62.01-58.3314.44
Other Investing Activities
3.114.746.53.431.412.21
Investing Cash Flow
-122.32-83.57-257.76-61.84-59.6212.2

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-1202412--
Long-Term Debt Issued
--3535--
Total Debt Issued
1341205947--
Short-Term Debt Repaid
--50-24-12--
Long-Term Debt Repaid
--36.98-35-43.48-33.47-7.52
Lease Payments
-1.98-1.98--43.48--
Total Debt Repaid
-65.98-86.98-59-55.48-33.47-7.52
Net Debt Issued (Repaid)
68.0233.02--8.48-33.47-7.52
Issuance of Common Stock
--225---
Common Dividends Paid
-63.61-63.61-79.52-46.62-33.3-62.16
Other Financing Activities
---0.02-0.20.29
Financing Cash Flow
4.4-30.6145.48-55.07-66.97-69.39

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-41.61-22.02-46.9-20.1730.653.26

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-177.43-237.232.6393.48156.0856.19
Free Cash Flow Growth
---97.19%-40.11%177.77%-29.67%
Free Cash Flow Margin
-30.95%-40.26%0.46%14.85%22.81%14.52%
Free Cash Flow Per Share
-5.55-7.420.083.475.792.09
Levered Free Cash Flow
-262.05-256.22-13.7370.08127.7340.35
Unlevered Free Cash Flow
-261.83-255.98-13.370.47127.9140.64
Free Cash Flow After Leases
-179.41-239.222.6350.01156.0856.19

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
1.030.370.250.620.320.42
Cash Income Tax Paid
19.1818.0843.3328.5312.0617.79
Change in Working Capital
1.753.171.02-19.6918.763.07